Titan Pharmaceuticals (NASDAQ:TTNP) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report issued on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Shares of NASDAQ:TTNP opened at $3.61 on Friday. Titan Pharmaceuticals has a 1-year low of $3.12 and a 1-year high of $14.80. The business has a 50-day moving average price of $3.86 and a two-hundred day moving average price of $5.12.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.